Literature DB >> 2941150

Autocrine beta-related interferon controls c-myc suppression and growth arrest during hematopoietic cell differentiation.

D Resnitzky, A Yarden, D Zipori, A Kimchi.   

Abstract

Different hematopoietic cells produce minute amounts of beta-related interferon (IFN) following induction of differentiation by chemical or natural inducers. The endogenous IFN binds to type I cell surface receptors and modulates gene expression in the producer cells. We show that self-induction of two members of the IFN-induced gene family differs in the dose response sensitivity and the prolonged kinetics of mRNA accumulation from the response to exogenous IFN-beta 1. Production and response to endogenous IFN are also detected when bone marrow precursor cells differentiate to macrophages after exposure to colony stimulating factor 1. In M1 myeloid cells induced to differentiate by lung-conditioned medium, addition of antibodies against IFN-beta partially abrogates the reduction of c-myc mRNA and the loss in cell proliferative activity, which both occur during differentiation. The endogenous IFN therefore functions as an autocrine growth inhibitor that participates in controlling c-myc suppression and the specific G0/G1 arrest during terminal differentiation of hematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2941150     DOI: 10.1016/0092-8674(86)90857-3

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  44 in total

1.  Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha.

Authors:  Raj Deonarain; Amit Verma; Andrew C G Porter; Dirk R Gewert; Leonidas C Platanias; Eleanor N Fish
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-03       Impact factor: 11.205

Review 2.  The cellular receptor of the alpha-beta interferons.

Authors:  K E Mogensen; G Uzé; P Eid
Journal:  Experientia       Date:  1989-06-15

3.  Partial characterization of a cellular factor that regulates the double-stranded RNA-dependent eIF-2 alpha kinase in 3T3-F442A fibroblasts.

Authors:  R Judware; R Petryshyn
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

4.  BALB/c-3T3 fibroblasts resistant to growth inhibition by beta interferon exhibit aberrant platelet-derived growth factor, epidermal growth factor, and fibroblast growth factor signal transduction.

Authors:  L J Mundschau; D V Faller
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

5.  DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation.

Authors:  Olga Moiseeva; Frédérick A Mallette; Utpal K Mukhopadhyay; Adrian Moores; Gerardo Ferbeyre
Journal:  Mol Biol Cell       Date:  2006-01-25       Impact factor: 4.138

6.  Regulation of 2',5'-oligoadenylate synthetase gene expression by interferons and platelet-derived growth factor.

Authors:  M A Garcia-Blanco; P Lengyel; E Morrison; C Brownlee; C D Stiles; M Rutherford; G Hannigan; B R Williams
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

7.  Granulocytic differentiation of HL-60 cells is not regulated by DNA de novo methylation.

Authors:  F Gieseler; P Meyer; D Schiffmann; K Wilms
Journal:  Blut       Date:  1989-03

8.  Interferons regulate the in vitro differentiation of multilineage lympho-myeloid stem cells in hairy cell leukemia.

Authors:  R Michalevicz; M Revel
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

9.  Recessive genetic deregulation abrogates c-myc suppression by interferon and is implicated in oncogenesis.

Authors:  A Kimchi; D Resnitzky; R Ber; G Gat
Journal:  Mol Cell Biol       Date:  1988-07       Impact factor: 4.272

10.  Autocrine induction of major histocompatibility complex class I antigen expression results from induction of beta interferon in oncogene-transformed BALB/c-3T3 cells.

Authors:  M K Offermann; D V Faller
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.